The Lancet Publishes 24-Month Results from Phase 3 Studies o

SYFOVRE demonstrated clinically meaningful reductions in GA lesion growth in as few as six doses per yearOnly treatment approved for use beyond 12...

Related Keywords

Waltham , Leicestershire , United Kingdom , Canada , United States , Switzerland , Australia , Texas , Jeffrey Heier , Charles Wykoff , Lissa Pavluk , Caroline Baumal , Meredith Kaya , Research Group , Twitter , Nasdaq , Linkedin , Exchange Commission On , Apellis Pharmaceuticals Inc , Exchange Commission , Lancet Glob Health , Retina Consultants , Eleonora Lad , Geographic Atrophy , Safety Information , Retinal Detachments , Vascular Endothelial Growth Factor , Prescribing Information , Forward Looking Statement , Private Securities Litigation Reform Act , Apelli Annual Report , Risk Factors , Apelli Quarterly Report ,